Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02773030 · OUTCOME

Cmax

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma · Source last updated 2026-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
ng/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)

What was measured

Cmax is defined as maximum plasma concentration of the drug.

Analysis population: All treated population with atleast 1 evaluable Pharmacokentic sample

Groups in this outcome

Cohort A: Treatment 1

CC220 0.30mg

Cohort A: Treatment 2

CC220 0.45mg

Cohort A: Treatment 3

CC220 0.60mg

Cohort A: Treatment 4

CC220 0.75mg

Cohort A: Treatment 5

CC220 0.90mg

Cohort A: Treatment 6

CC220 1.0mg

Cohort B: Treatment 1

CC220 0.30mg + DEX

Cohort B: Treatment 2

CC220 0.45mg + DEX

Cohort B: Treatment 3

CC220 0.60mg + DEX

Cohort B: Treatment 4

CC220 0.75mg + DEX

Cohort B: Treatment 5

CC220 0.90mg + DEX

Cohort B: Treatment 6

CC220 1.0mg + DEX

Cohort B: Treatment 7

CC220 1.1mg + DEX

Cohort B: Treatment 8

CC220 1.2mg + DEX

Cohort B: Treatment 9

CC220 1.3.mg + DEX

Cohort B: Treatment 10

CC220 1.6mg + DEX

Cohort D: Treatment 1

CC220 + DEX

Cohort E: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort E: Treatment 2

CC220 1.1mg + DARA + DEX

Cohort E: Treatment 3

CC220 1.2mg + DARA + DEX

Cohort E: Treatment 4

CC220 1.3mg + DARA + DEX

Cohort E: Treatment 5

CC220 1.6mg + DARA + DEX

Cohort F: Treatment 1

CC220 1.0mg + BORT + DEX

Cohort F: Treatment 2

CC220 1.1mg + BORT + DEX

Cohort F: Treatment 3

CC220 1.3mg + BORT + DEX

Cohort F: Treatment 4

CC220 1.6mg + BORT + DEX

Cohort G: Treatment 1

CC220 1.1mg + CFZ + DEX

Cohort G: Treatment 2

CC220 1.3mg + CFZ + DEX

Cohort G: Treatment 3

CC220 1.6mg + CFZ + DEX

Cohort H1

CC220 + DEX

Cohort H2

CC220 + DEX

Cohort I

CC220 + DEX

Cohort J1: Treatment 1

CC220Vd 1.0mg + NE-ASCT

Cohort J1: Treatment 2

CC220Vd 1.6mg + NE-ASCT

Cohort K: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort K: Treatment 2

CC220 1.3mg + DARA + DEX

Cohort K: Treatment 3

CC220 1.6mg + DARA + DEX

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort A: Treatment 11
Cohort A: Treatment 22
Cohort A: Treatment 31
Cohort A: Treatment 42
Cohort A: Treatment 50
Cohort A: Treatment 60
Cohort B: Treatment 11
Cohort B: Treatment 20
Cohort B: Treatment 31
Cohort B: Treatment 40
Cohort B: Treatment 52
Cohort B: Treatment 62
Cohort B: Treatment 72
Cohort B: Treatment 81
Cohort B: Treatment 91
Cohort B: Treatment 102
Cohort D: Treatment 19
Cohort E: Treatment 11
Cohort E: Treatment 21
Cohort E: Treatment 31
Cohort E: Treatment 41
Cohort E: Treatment 50
Cohort F: Treatment 11
Cohort F: Treatment 20
Cohort F: Treatment 31
Cohort F: Treatment 40
Cohort G: Treatment 11
Cohort G: Treatment 21
Cohort G: Treatment 30
Cohort H16
Cohort H20
Cohort I0
Cohort J1: Treatment 10
Cohort J1: Treatment 20
Cohort K: Treatment 10
Cohort K: Treatment 20
Cohort K: Treatment 30

Reported measurements

CC-220

Analysis denominator · Participants

GroupSource count
Cohort A: Treatment 11
Cohort A: Treatment 22
Cohort A: Treatment 31
Cohort A: Treatment 42
Cohort A: Treatment 50
Cohort A: Treatment 60
Cohort B: Treatment 11
Cohort B: Treatment 20
Cohort B: Treatment 31
Cohort B: Treatment 40
Cohort B: Treatment 52
Cohort B: Treatment 62
Cohort B: Treatment 72
Cohort B: Treatment 81
Cohort B: Treatment 91
Cohort B: Treatment 102
Cohort D: Treatment 19
Cohort E: Treatment 11
Cohort E: Treatment 21
Cohort E: Treatment 31
Cohort E: Treatment 41
Cohort E: Treatment 50
Cohort F: Treatment 11
Cohort F: Treatment 20
Cohort F: Treatment 31
Cohort F: Treatment 40
Cohort G: Treatment 11
Cohort G: Treatment 21
Cohort G: Treatment 30
Cohort H16
Cohort H20
Cohort I0
Cohort J1: Treatment 10
Cohort J1: Treatment 20
Cohort K: Treatment 10
Cohort K: Treatment 20
Cohort K: Treatment 30
Values in ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Cohort A: Treatment 11.5200NANot reportedNot reportedInsufficient number of participants to calculate
Cohort A: Treatment 21.794415.4287Not reportedNot reportedNot reported
Cohort A: Treatment 310.7000NANot reportedNot reportedInsufficient number of participants to calculate
Cohort A: Treatment 45.592928.1747Not reportedNot reportedNot reported
Cohort B: Treatment 11.7600NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 34.7800NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 59.9124267.2801Not reportedNot reportedNot reported
Cohort B: Treatment 63.501764.5111Not reportedNot reportedNot reported
Cohort B: Treatment 78.2704172.8969Not reportedNot reportedNot reported
Cohort B: Treatment 87.5100NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 99.9200NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 107.462732.8756Not reportedNot reportedNot reported
Cohort D: Treatment 112.118339.8083Not reportedNot reportedNot reported
Cohort E: Treatment 12.5200NANot reportedNot reportedInsufficient number of participants to calculate
Cohort E: Treatment 213.0000NANot reportedNot reportedInsufficient number of participants to calculate
Cohort E: Treatment 313.9000NANot reportedNot reportedInsufficient number of participants to calculate
Cohort E: Treatment 46.6900NANot reportedNot reportedInsufficient number of participants to calculate
Cohort F: Treatment 11.3300NANot reportedNot reportedInsufficient number of participants to calculate
Cohort F: Treatment 319.8000NANot reportedNot reportedInsufficient number of participants to calculate
Cohort G: Treatment 15.1600NANot reportedNot reportedInsufficient number of participants to calculate
Cohort G: Treatment 26.4300NANot reportedNot reportedInsufficient number of participants to calculate
Cohort H115.341179.6863Not reportedNot reportedNot reported
CC-17195

Analysis denominator · Participants

GroupSource count
Cohort A: Treatment 10
Cohort A: Treatment 20
Cohort A: Treatment 31
Cohort A: Treatment 42
Cohort A: Treatment 50
Cohort A: Treatment 60
Cohort B: Treatment 10
Cohort B: Treatment 20
Cohort B: Treatment 31
Cohort B: Treatment 40
Cohort B: Treatment 52
Cohort B: Treatment 61
Cohort B: Treatment 72
Cohort B: Treatment 81
Cohort B: Treatment 91
Cohort B: Treatment 102
Cohort D: Treatment 19
Cohort E: Treatment 10
Cohort E: Treatment 21
Cohort E: Treatment 31
Cohort E: Treatment 40
Cohort E: Treatment 50
Cohort F: Treatment 10
Cohort F: Treatment 20
Cohort F: Treatment 31
Cohort F: Treatment 40
Cohort G: Treatment 11
Cohort G: Treatment 21
Cohort G: Treatment 30
Cohort H16
Cohort H20
Cohort I0
Cohort J1: Treatment 10
Cohort J1: Treatment 20
Cohort K: Treatment 10
Cohort K: Treatment 20
Cohort K: Treatment 30
Values in ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Cohort A: Treatment 30.2980NANot reportedNot reportedInsufficient number of participants to calculate
Cohort A: Treatment 40.15019.9068Not reportedNot reportedNot reported
Cohort B: Treatment 30.2240NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 50.4188103.5840Not reportedNot reportedNot reported
Cohort B: Treatment 60.1610NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 70.3475104.8825Not reportedNot reportedNot reported
Cohort B: Treatment 80.3480NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 90.3550NANot reportedNot reportedInsufficient number of participants to calculate
Cohort B: Treatment 100.358830.8149Not reportedNot reportedNot reported
Cohort D: Treatment 10.533051.5168Not reportedNot reportedNot reported
Cohort E: Treatment 20.3050NANot reportedNot reportedInsufficient number of participants to calculate
Cohort E: Treatment 30.6700Not reportedNot reportedNot reportedNot reported
Cohort F: Treatment 30.7240Not reportedNot reportedNot reportedNot reported
Cohort G: Treatment 10.2430NANot reportedNot reportedInsufficient number of participants to calculate
Cohort G: Treatment 20.2900NANot reportedNot reportedInsufficient number of participants to calculate
Cohort H10.995760.6459Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Insufficient number of participants to calculate
        group Id
        OG000
        spread
        NA
        value
        1.5200
      2. group Id
        OG001
        spread
        15.4287
        value
        1.7944
      3. comment
        Insufficient number of participants to calculate
        group Id
        OG002
        spread
        NA
        value
        10.7000
      4. group Id
        OG003
        spread
        28.1747
        value
        5.5929
      5. comment
        Insufficient number of participants to calculate
        group Id
        OG006
        spread
        NA
        value
        1.7600
      6. comment
        Insufficient number of participants to calculate
        group Id
        OG008
        spread
        NA
        value
        4.7800
      7. group Id
        OG010
        spread
        267.2801
        value
        9.9124
      8. group Id
        OG011
        spread
        64.5111
        value
        3.5017
      9. group Id
        OG012
        spread
        172.8969
        value
        8.2704
      10. comment
        Insufficient number of participants to calculate
        group Id
        OG013
        spread
        NA
        value
        7.5100
      11. comment
        Insufficient number of participants to calculate
        group Id
        OG014
        spread
        NA
        value
        9.9200
      12. group Id
        OG015
        spread
        32.8756
        value
        7.4627
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        1
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        1
      10. group Id
        OG009
        value
        0
      11. group Id
        OG010
        value
        2
      12. group Id
        OG011
        value
        2
      units
      Participants
    title
    CC-220
  2. categories
    1. measurements
      1. comment
        Insufficient number of participants to calculate
        group Id
        OG002
        spread
        NA
        value
        0.2980
      2. group Id
        OG003
        spread
        9.9068
        value
        0.1501
      3. comment
        Insufficient number of participants to calculate
        group Id
        OG008
        spread
        NA
        value
        0.2240
      4. group Id
        OG010
        spread
        103.5840
        value
        0.4188
      5. comment
        Insufficient number of participants to calculate
        group Id
        OG011
        spread
        NA
        value
        0.1610
      6. group Id
        OG012
        spread
        104.8825
        value
        0.3475
      7. comment
        Insufficient number of participants to calculate
        group Id
        OG013
        spread
        NA
        value
        0.3480
      8. comment
        Insufficient number of participants to calculate
        group Id
        OG014
        spread
        NA
        value
        0.3550
      9. group Id
        OG015
        spread
        30.8149
        value
        0.3588
      10. group Id
        OG016
        spread
        51.5168
        value
        0.5330
      11. comment
        Insufficient number of participants to calculate
        group Id
        OG018
        spread
        NA
        value
        0.3050
      12. group Id
        OG019
        value
        0.6700
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        1
      10. group Id
        OG009
        value
        0
      11. group Id
        OG010
        value
        2
      12. group Id
        OG011
        value
        1
      units
      Participants
    title
    CC-17195
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      1
    4. group Id
      OG003
      value
      2
    5. group Id
      OG004
      value
      0
    6. group Id
      OG005
      value
      0
    7. group Id
      OG006
      value
      1
    8. group Id
      OG007
      value
      0
    9. group Id
      OG008
      value
      1
    10. group Id
      OG009
      value
      0
    11. group Id
      OG010
      value
      2
    12. group Id
      OG011
      value
      2
    units
    Participants
description
Cmax is defined as maximum plasma concentration of the drug.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    CC220 0.30mg
    id
    OG000
    title
    Cohort A: Treatment 1
  2. description
    CC220 0.45mg
    id
    OG001
    title
    Cohort A: Treatment 2
  3. description
    CC220 0.60mg
    id
    OG002
    title
    Cohort A: Treatment 3
  4. description
    CC220 0.75mg
    id
    OG003
    title
    Cohort A: Treatment 4
  5. description
    CC220 0.90mg
    id
    OG004
    title
    Cohort A: Treatment 5
  6. description
    CC220 1.0mg
    id
    OG005
    title
    Cohort A: Treatment 6
  7. description
    CC220 0.30mg + DEX
    id
    OG006
    title
    Cohort B: Treatment 1
  8. description
    CC220 0.45mg + DEX
    id
    OG007
    title
    Cohort B: Treatment 2
  9. description
    CC220 0.60mg + DEX
    id
    OG008
    title
    Cohort B: Treatment 3
  10. description
    CC220 0.75mg + DEX
    id
    OG009
    title
    Cohort B: Treatment 4
  11. description
    CC220 0.90mg + DEX
    id
    OG010
    title
    Cohort B: Treatment 5
  12. description
    CC220 1.0mg + DEX
    id
    OG011
    title
    Cohort B: Treatment 6
param Type
GEOMETRIC_MEAN
population Description
All treated population with atleast 1 evaluable Pharmacokentic sample
reporting Status
POSTED
time Frame
From Cycle 1 Day 1 to Cycle 1 Day 15 (15 days)
title
Cmax
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice